Renin inhibitor
Renin inhibitor | |
---|---|
C09XA | |
Biological target | Renin |
Clinical data | |
Drugs.com | Drug Classes |
Legal status | |
In Wikidata |
Renin inhibitors are
Renin inhibitor is often preceded by direct, called direct renin inhibitor in order to distinguish its mechanism from other
These drugs
History
In 1896, the Finnish physiologist
Aliskiren, the only renin inhibitor to go into phase III clinical trials, is not structurally related to peptides, which makes it a third-generation renin inhibitor.
The renin–angiotensin–aldosterone system
The
The highly
It is suspected that essential hypertension, a heterogeneous disorder whose long-term effects can be end organ damage, can involve at least in some cases an overactivity of this system, which several types of medications attempt to counter.[21] Renin concentration in blood plasma tends to be higher in younger people with hypertension when vasoconstriction may be the main reason for high blood pressure. Conversely, renin is lower in older people or in people of African American or African Caribbean ethnicity when salt retention may contribute more to elevated blood pressure.[21] However, the role of plasma renin levels in the etiology and management of hypertension is disputed.[24]
Mechanism of action
Renin inhibitors bind to the
Drug discovery and development
Pepstatin – the first renin inhibitor
First generation: peptide analogues
This generation consists of two groups of compounds, either peptide analogues of the prosegment of renin
Second generation: peptide mimetics
Compounds in this generation were more potent, more stable and had longer durations of action. One of these, CGP2928, a peptidomimetic compound, was the first renin inhibitor proven effective when taken orally. Tested on marmosets, it was only active at high doses.[12] Development of new drugs in the second generation continued to improve pharmacokinetic properties. Remikiren, enalkiren and zankiren were then discovered. These were peptidomimetic inhibitors with improved structures that made them more specific, potent and stable. Unfortunately, clinical development was terminated because the drugs had poor oral bioavailability (poorly absorbed and rapidly metabolized) and lowering blood pressure activity still remained low.[7][22][28]
Third generation: non-peptides
However, caused by their chemical structure even third-generation renin inhibitors are difficult to resorb by the human body and their oral bioavailability is often below 2%.
Binding and structure activity relationship of renin inhibitors
The renin molecule is a monospecific enzyme that belongs to the aspartic protease family.[41] Its structure is complex and consists of two homologous lobes that fold mainly in a β-sheet conformation.[22] Between the two lobes, deep within the enzyme, resides the active site, and its catalytic activity is due to two aspartic acid residues (Asp32 and Asp 215, one from each lobe in the renin molecule).[42] A flexible flap made from amino acids formed in a β-hairpin closes the active site by covering the cleft.[43] The renin molecule contains both hydrophobic and
Characteristics[11] | Subsite | Importance to binding[11][46] | |
---|---|---|---|
S4 | Hydrophobic | P4 | Relatively important for binding |
S3 | Hydrophobic | P3 | Very important for binding |
S3sp | Equally hydrophobic/-philic | P3 side chain | Dramatically enhances binding affinity |
S2 | Large and hydrophobic | P2 | Important for binding |
S1 | Large and hydrophobic | P1 | NA |
S1′ | Primarily hydrophobic | P1′ | Critical for tight binding |
S2′ | Polar | P2′ | Critical for tight binding |
S3′ | NA | P3′ | Structure and presence is not as important |
Interaction with both aspartic acids in the active site results in a higher affinity. Higher affinity also results by occupying more active site pockets. However, some pockets contribute more to the affinity than others. A hydrophobic interaction with the S3sp subpocket, S1 and S3 contribute to higher potency and affinity.[47] By having a large and
Example of binding to the renin inhibitor: Aliskiren is a peptide-like renin inhibitor and, unlike most, it is rather hydrophilic. It blocks the catalytic function of the enzyme by occupying the S3 to S2′ pockets, except the S2 pocket. Aliskiren also binds to the S3sp subpocket and because that pocket is distinct for renin, aliskiren does not inhibit other aspartic proteases, such as cathepsin D and pepsin.[46] The side chain of aliskiren binds the S3sp subpocket ideally, and leads to its quality as an inhibitor of human renin.[11] The hydroxyl group in aliskiren forms a hydrogen bond with both oxygen atoms of the
Current status
Aliskiren is effective in lowering blood pressure,[7][28] but as of 20 April 2012 the US Food and Drug Administration (FDA) issued a warning of possible risks when using aliskiren or blood pressure medicines containing aliskiren with ACE inhibitors and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment. They advised that such drug combinations should not be used in patients with diabetes because of the risk of causing renal impairment, hypotension, and hyperkalemia and that aliskiren should not be used with ARBs or ACE inhibitors in patients with moderate to severe renal impairment (i.e., where glomerular filtration rate [GFR] < 60 mL/min). However, they also recommend that patients should not stop taking aliskiren without talking to a healthcare professional.[50]
Aliskiren in combination with hydrochlorothiazide was approved by the FDA in 2008 under the tradename Tekturna HCT.[51][52]
In 2007, Actelion/Merck and Speedel companies announced they had the next generation of renin inhibitors in clinical research. The lead compound from Actelion/Merck has entered phase II trials. One compound from Speedel, SPP635, has completed phase IIa. The results showed it was safe and well tolerated over a four-week period, and it reduced blood pressure by 9.8 to 17.9 mmHg. In 2008, SPP635 was continuing phase II development for hypertension in
The next generation of renin inhibitors have shown potential improvements over previous generations where bioavailability has increased up to 30% in humans, and they have better tissue distribution.[51][unreliable source]
See also
- ACE inhibitor
- ACE inhibitors drug design
- Angiotensin
- Angiotensin II receptor antagonist
- Beta blocker
- Circulatory system
- Discovery and development of angiotensin receptor blockers
References
- PMID 15723979.
- ^ "Renin Inhibitors". CV Pharmacology. Retrieved 2020-07-22.
- ISBN 978-0-12-802393-8.
- ^ "The Renin-Angiotensin-Aldosterone-System". TeachMePhysiology. 2020-04-28. Retrieved 2020-07-22.
- ISBN 978-0-7216-0258-5.
- ^ ISBN 978-1-4557-4617-0.
- ^ S2CID 19633316.
- ^ S2CID 8348522.
- ^ S2CID 739207.
- ^ PMID 11390864.
- ^ PMID 20731374.
- ^ PMID 3928488.
- ^ S2CID 4306900.
- PMID 17556409.
- PMID 11799102.
- PMID 18843743.
- PMID 18035185.
- ^ PMID 20393195.
- PMID 19457666.
- ^ PMID 17083068.
- ^ S2CID 73232791.
- ^ PMID 10903938.
- ^ S2CID 23032701.
- S2CID 221263755.
- S2CID 23697321.
- PMID 20409858.
- PMID 21293386.
- ^ S2CID 20729350.
- PMID 4912600.
- PMID 15703270.
- PMID 385457.
- PMID 394302.
- PMID 993206.
- PMID 7034718.
- PMID 3894354.
- PMID 7040240.
- PMID 6398331.
- PMID 3910726.
- PMID 24143271.
- S2CID 221550002.
- ^ PMID 20635532.
- PMID 18237679.
- ^ PMID 8254610.
- PMID 21840215.
- ^ PMID 21741239.
- ^ PMID 12927775.
- ^ PMID 20855222.
- PMID 3884499.
- PMID 21708467.
- ^ "Aliskiren-containing Medications: Drug Safety Comunication [sic]- New Warning and Contraindication". www.fda.gov. Archived from the original on 2012-04-22.
- ^ a b c Speedel Acquiring an additional 51.7% stake and announcing plans for mandatory public tender offer.TRANSACTION OVERVIEW. (2008). From Novartis: http://www.novartis.com/downloads/investors/presentations-events/other-events/2008/2008-07_speedel-backgrounder.pdf
- ^ Tekturna HCT (aliskiren; hydrochlorothiazide) tablets. (2011). From US Food and Drug Administration: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022107s009lbl.pdf
External links
- The Story of Aliskiren the first Renin Inhibitor - drugdesign.org
- Renin inhibitor aliskiren leads to dose-dependent blood pressure reductions - medicalnewstoday.com.